受体相互作用蛋白激酶1 (RIPK1)的分子和功能特征及其在阿尔茨海默病中的治疗潜力

IF 6.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY Drug Discovery Today Pub Date : 2023-08-24 DOI:10.1016/j.drudis.2023.103750
Satyam Pati, Avtar Singh Gautam, Mangaldeep Dey, Aman Tiwari, Rakesh Kumar Singh
{"title":"受体相互作用蛋白激酶1 (RIPK1)的分子和功能特征及其在阿尔茨海默病中的治疗潜力","authors":"Satyam Pati,&nbsp;Avtar Singh Gautam,&nbsp;Mangaldeep Dey,&nbsp;Aman Tiwari,&nbsp;Rakesh Kumar Singh","doi":"10.1016/j.drudis.2023.103750","DOIUrl":null,"url":null,"abstract":"<div><p>Inflammation and cell death processes positively control the organ homeostasis of an organism. Receptor-interacting protein kinase 1 (RIPK1), a member of the RIPK family, is a crucial regulator of cell death and inflammation, and control homeostasis at the cellular and tissue level. Necroptosis, a programmed form of necrosis-mediated cell death and tumor necrosis factor (TNF)-induced necrotic cell death, is mostly regulated by RIPK1 kinase activity. Thus, RIPK1 has recently emerged as an upstream kinase that controls multiple cellular pathways and participates in regulating inflammation and cell death. All the major cell types in the central nervous system (CNS) have been found to express RIPK1. Selective inhibition of RIPK1 has been shown to prevent neuronal cell death, which could ultimately lead to a significant reduction of neurodegeneration and neuroinflammation. In addition, the kinase structure of RIPK1 is highly conducive to the development of specific pharmacological small-molecule inhibitors. These factors have led to the emergence of RIPK1 as an important therapeutic target for Alzheimer’s disease (AD).</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"28 12","pages":"Article 103750"},"PeriodicalIF":6.5000,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease\",\"authors\":\"Satyam Pati,&nbsp;Avtar Singh Gautam,&nbsp;Mangaldeep Dey,&nbsp;Aman Tiwari,&nbsp;Rakesh Kumar Singh\",\"doi\":\"10.1016/j.drudis.2023.103750\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Inflammation and cell death processes positively control the organ homeostasis of an organism. Receptor-interacting protein kinase 1 (RIPK1), a member of the RIPK family, is a crucial regulator of cell death and inflammation, and control homeostasis at the cellular and tissue level. Necroptosis, a programmed form of necrosis-mediated cell death and tumor necrosis factor (TNF)-induced necrotic cell death, is mostly regulated by RIPK1 kinase activity. Thus, RIPK1 has recently emerged as an upstream kinase that controls multiple cellular pathways and participates in regulating inflammation and cell death. All the major cell types in the central nervous system (CNS) have been found to express RIPK1. Selective inhibition of RIPK1 has been shown to prevent neuronal cell death, which could ultimately lead to a significant reduction of neurodegeneration and neuroinflammation. In addition, the kinase structure of RIPK1 is highly conducive to the development of specific pharmacological small-molecule inhibitors. These factors have led to the emergence of RIPK1 as an important therapeutic target for Alzheimer’s disease (AD).</p></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"28 12\",\"pages\":\"Article 103750\"},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2023-08-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644623002660\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644623002660","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

炎症和细胞死亡过程积极地控制着生物体的器官稳态。受体相互作用蛋白激酶1 (Receptor-interacting protein kinase 1, RIPK1)是RIPK家族的一员,是细胞死亡和炎症的重要调节因子,并在细胞和组织水平上控制稳态。坏死坏死是一种程序化的坏死介导的细胞死亡和肿瘤坏死因子(TNF)诱导的坏死细胞死亡,主要受RIPK1激酶活性的调节。因此,RIPK1最近作为一种控制多种细胞通路并参与调节炎症和细胞死亡的上游激酶而出现。中枢神经系统(CNS)的所有主要细胞类型都被发现表达RIPK1。选择性抑制RIPK1已被证明可以防止神经元细胞死亡,这可能最终导致神经变性和神经炎症的显著减少。此外,RIPK1的激酶结构非常有利于开发特异性药理小分子抑制剂。这些因素导致RIPK1成为阿尔茨海默病(AD)的重要治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease

Inflammation and cell death processes positively control the organ homeostasis of an organism. Receptor-interacting protein kinase 1 (RIPK1), a member of the RIPK family, is a crucial regulator of cell death and inflammation, and control homeostasis at the cellular and tissue level. Necroptosis, a programmed form of necrosis-mediated cell death and tumor necrosis factor (TNF)-induced necrotic cell death, is mostly regulated by RIPK1 kinase activity. Thus, RIPK1 has recently emerged as an upstream kinase that controls multiple cellular pathways and participates in regulating inflammation and cell death. All the major cell types in the central nervous system (CNS) have been found to express RIPK1. Selective inhibition of RIPK1 has been shown to prevent neuronal cell death, which could ultimately lead to a significant reduction of neurodegeneration and neuroinflammation. In addition, the kinase structure of RIPK1 is highly conducive to the development of specific pharmacological small-molecule inhibitors. These factors have led to the emergence of RIPK1 as an important therapeutic target for Alzheimer’s disease (AD).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Discovery Today
Drug Discovery Today 医学-药学
CiteScore
14.80
自引率
2.70%
发文量
293
审稿时长
6 months
期刊介绍: Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
期刊最新文献
Efficacy and challenges involving combination therapies in CLL. Strategic partnerships for AI-driven drug discovery: The role of relational dynamics. Antibody-drug conjugates: prospects for the next generation. Improving access to domestic innovative medicines: characteristics and trends of approved drugs in China 2010-2024. Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1